| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yihang Pan | |
| Changbo Qu | |||
| Gwenny M. Fuhler | |||
| P2860 | cites work | SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development | Q107102113 |
| CONTROL OF GASTRIC ACID SECRETION | Q107102116 | ||
| The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication | Q107102118 | ||
| A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19 | Q107102119 | ||
| Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19 | Q107102120 | ||
| Mast cell stabilizers as a supportive therapy can contribute to alleviate fatal inflammatory responses and severity of pulmonary complications in COVID-19 infection | Q107102121 | ||
| Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia | Q107102122 | ||
| Histamine H4 receptor is a potential target for COVID-19 treatment | Q107102123 | ||
| Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP | Q107102124 | ||
| Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins—An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic | Q107102125 | ||
| COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms | Q107102126 | ||
| Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 | Q107102127 | ||
| Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs | Q107102128 | ||
| A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection | Q107102129 | ||
| Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element. | Q50556738 | ||
| A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase. | Q54217786 | ||
| Mast Cell-Derived Histamine Regulates Liver Ketogenesis via Oleoylethanolamide Signaling | Q57483515 | ||
| Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents | Q59353237 | ||
| Histamine and Delirium: Current Opinion | Q64063456 | ||
| Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China | Q83767469 | ||
| First Case of 2019 Novel Coronavirus in the United States | Q84109660 | ||
| The histamine H3 receptor: an attractive target for the treatment of cognitive disorders | Q24654788 | ||
| Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis. | Q30376160 | ||
| Molecular properties and signalling pathways of the histamine H1 receptor | Q33709711 | ||
| H1-receptor antagonists: safety issues | Q33785375 | ||
| Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice | Q34033317 | ||
| Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. | Q34470890 | ||
| The H1 histamine receptor regulates allergic lung responses. | Q34567414 | ||
| Interspecies transmission and emergence of novel viruses: lessons from bats and birds | Q34774311 | ||
| The H1-receptor antagonist cetirizine ameliorates high-fat diet-induced glucose intolerance in male C57BL/6 mice, but not diabetes outcome in female non-obese diabetic (NOD) mice | Q35308853 | ||
| H1-receptors: localization and role in airway physiology and in immune functions | Q35552822 | ||
| Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists | Q35706815 | ||
| Histamine receptor signaling in energy homeostasis | Q36391171 | ||
| The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines | Q37049023 | ||
| Use of corticosteroids in treating infectious diseases | Q37173624 | ||
| Prescription practice of antihistamines for acute upper respiratory tract infections in pediatric patients in a local emergency department in Hong Kong | Q37604034 | ||
| Diverse macrophage populations mediate acute lung inflammation and resolution | Q37707609 | ||
| Histamine, histamine receptors and antihistamines: new concepts | Q37762461 | ||
| Host and viral traits predict zoonotic spillover from mammals | Q38668458 | ||
| Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. | Q38997064 | ||
| The Mechanism of Histamine Binding to Heparin | Q39252549 | ||
| Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms | Q39979447 | ||
| Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection | Q40178889 | ||
| Seizure susceptibility due to antihistamines in febrile seizures | Q40363396 | ||
| Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor. | Q42471038 | ||
| Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors | Q43749173 | ||
| Effects of antihistamines on innate immune responses to severe bacterial infection in mice | Q44153440 | ||
| Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades | Q45225358 | ||
| Quantitative characterization of the binding of histamine by heparin. | Q45952064 | ||
| Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. | Q47548651 | ||
| Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway | Q47560712 | ||
| Pathological findings of COVID-19 associated with acute respiratory distress syndrome | Q87281430 | ||
| SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor | Q88292103 | ||
| A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | Q88370045 | ||
| Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study | Q88486721 | ||
| Doxepin in Children and Adolescents with Symptoms of Insomnia: A Single Center Experience | Q89580016 | ||
| Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 | Q89973070 | ||
| The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 | Q91240147 | ||
| COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? | Q91638688 | ||
| FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-κB-RIPK1-caspase axis | Q92639760 | ||
| Drug treatment options for the 2019-new coronavirus (2019-nCoV) | Q93038127 | ||
| COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin | Q93256585 | ||
| Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study | Q94446884 | ||
| A SARS-CoV-2 protein interaction map reveals targets for drug repurposing | Q94470555 | ||
| Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs | Q94520529 | ||
| COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence? | Q94520588 | ||
| Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions | Q94588769 | ||
| Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients | Q94679904 | ||
| Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial | Q94685789 | ||
| SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues | Q94938805 | ||
| Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids | Q94942446 | ||
| Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19 | Q94959545 | ||
| Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing | Q95308075 | ||
| Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study | Q95633343 | ||
| Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review) | Q95937520 | ||
| Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence | Q96122325 | ||
| Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series | Q96134314 | ||
| Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 | Q96225001 | ||
| Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities | Q96235014 | ||
| Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach | Q96438009 | ||
| Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis | Q96953959 | ||
| Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report | Q97551976 | ||
| Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates | Q97650827 | ||
| In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication | Q98205148 | ||
| The type I interferon response in COVID-19: implications for treatment | Q98394813 | ||
| Dual-Histamine Receptor Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients | Q98881897 | ||
| Coronavirus 2019, Microthromboses, and Platelet Activating Factor | Q98944307 | ||
| Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study | Q99413341 | ||
| Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2 | Q99630792 | ||
| SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 | Q99707959 | ||
| An in-silico evaluation of COVID-19 main protease with clinically approved drugs | Q100422416 | ||
| Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | Q100500963 | ||
| Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis | Q100518589 | ||
| Drug inhibition of SARS-CoV-2 replication in human pluripotent stem cell-derived intestinal organoids | Q102056980 | ||
| JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality | Q102058584 | ||
| Histamine receptors and COVID-19 | Q102146996 | ||
| Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain | Q104280984 | ||
| Identification of antiviral antihistamines for COVID-19 repurposing | Q104289159 | ||
| NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients | Q104574829 | ||
| A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry | Q106464750 | ||
| A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection | Q106464817 | ||
| Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2 | Q107033464 | ||
| Repositioning of histamine H receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2 | Q107073208 | ||
| Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis | Q107073292 | ||
| Severe urticarial rash as the initial symptom of COVID-19 infection | Q107102114 | ||
| Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients | Q107102115 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P921 | main subject | pharmacology | Q128406 |
| SARS-CoV-2 | Q82069695 | ||
| COVID-19 | Q84263196 | ||
| P304 | page(s) | 5672 | |
| P577 | publication date | 2021-05-26 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19? | |
| P478 | volume | 22 |
Search more.